Market revenue in 2024 | USD 379.5 million |
Market revenue in 2030 | USD 1,118.8 million |
Growth rate | 19.9% (CAGR from 2025 to 2030) |
Largest segment | Pre-commercial/ r&d scale |
Fastest growing segment | Commercial Scale |
Historical data covered | 2018 - 2023 |
Base year for estimation | 2024 |
Forecast period covered | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pre-commercial/ R&D Scale, Commercial Scale |
Key market players worldwide | Miltenyi Biotec, Lonza Group Ltd, Fresenius SE & Co KGaA, Cytiva, Terumo Corp, Sartorius AG, ThermoGenesis Holdings Inc, Thermo Fisher Scientific Inc, Biospherix, Cellares |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to automated and closed cell therapy processing systems market will help companies and investors design strategic landscapes.
Pre-commercial/ r&d scale was the largest segment with a revenue share of 87.46% in 2024. Horizon Databook has segmented the Europe automated and closed cell therapy processing systems market based on pre-commercial/ r&d scale, commercial scale covering the revenue growth of each sub-segment from 2018 to 2030.
A strong workforce in European countries and a strong facility network is anticipated to fuel the market growth in the region. Over the recent year, through European research initiatives, a series of fully automated platforms were introduced which capable of supporting the bioprocess from start to end.
Stem Cell Factory is one such example that is a fully automated production unit for Cultivation, reprogramming, and differentiation iPSCs (induced pluripotent stem cells). In addition, AUTOSTEM fully automated platform is one of the versatile platforms that allow for a fully automated manufacturing and banking of cell therapies undertaking a donor-to-patient approach.
Furthermore, increasing funding for gene and cell therapy is expected to further fuel the market growth. For instance, in the first half of 2020, European companies developing advanced therapies such as cell & gene therapies secured at least USD 2.6B. Moreover, in September 2021, TreeFrog Therapeutics raised USD 75.6 million series B funding to provide stem cell-derived cell therapies for patients.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe automated and closed cell therapy processing systems market , including forecasts for subscribers. This continent databook contains high-level insights into Europe automated and closed cell therapy processing systems market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account